HBK Sorce Advisory LLC bought a new stake in shares of Becton Dickinson and Co (NYSE:BDX) in the fourth quarter, HoldingsChannel reports. The fund bought 3,961 shares of the medical instruments supplier’s stock, valued at approximately $848,000.

Other institutional investors also recently added to or reduced their stakes in the company. Zions Bancorporation grew its position in shares of Becton Dickinson and by 23.7% during the 3rd quarter. Zions Bancorporation now owns 10,718 shares of the medical instruments supplier’s stock valued at $2,100,000 after acquiring an additional 2,050 shares during the period. BlackRock Inc. grew its position in shares of Becton Dickinson and by 6.0% during the 4th quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock valued at $4,026,750,000 after acquiring an additional 1,071,288 shares during the period. SevenBridge Financial Group LLC grew its position in shares of Becton Dickinson and by 5.2% during the 3rd quarter. SevenBridge Financial Group LLC now owns 12,579 shares of the medical instruments supplier’s stock valued at $2,465,000 after acquiring an additional 622 shares during the period. Cigna Investments Inc. New grew its position in shares of Becton Dickinson and by 11.8% during the 4th quarter. Cigna Investments Inc. New now owns 9,741 shares of the medical instruments supplier’s stock valued at $2,085,000 after acquiring an additional 1,025 shares during the period. Finally, Macquarie Group Ltd. boosted its holdings in Becton Dickinson and by 17.5% in the 3rd quarter. Macquarie Group Ltd. now owns 93,453 shares of the medical instruments supplier’s stock worth $18,312,000 after buying an additional 13,900 shares during the period. 83.37% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Becton Dickinson and Co (NYSE BDX) opened at $223.27 on Friday. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. Becton Dickinson and Co has a fifty-two week low of $175.66 and a fifty-two week high of $248.39. The company has a market cap of $59,678.25, a price-to-earnings ratio of 23.25, a price-to-earnings-growth ratio of 1.63 and a beta of 1.18.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the firm earned $2.33 EPS. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. equities research analysts anticipate that Becton Dickinson and Co will post 10.94 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be issued a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.34%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s payout ratio is 229.01%.

In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the transaction, the director now directly owns 295,753 shares of the company’s stock, valued at approximately $64,420,918.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Timothy M. Ring sold 176 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $218.27, for a total transaction of $38,415.52. Following the completion of the transaction, the director now directly owns 170,688 shares of the company’s stock, valued at $37,256,069.76. The disclosure for this sale can be found here. Over the last three months, insiders sold 281,108 shares of company stock valued at $61,321,396. Insiders own 1.00% of the company’s stock.

Several research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Tuesday, March 6th. BMO Capital Markets assumed coverage on shares of Becton Dickinson and in a report on Monday, March 5th. They issued a “market perform” rating and a $249.00 price objective for the company. Morgan Stanley raised their price objective on shares of Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 7th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $260.00 price objective (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Finally, Bank of America reaffirmed a “buy” rating and issued a $260.00 price objective on shares of Becton Dickinson and in a report on Friday, January 19th. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $238.00.

WARNING: “HBK Sorce Advisory LLC Buys Shares of 3,961 Becton Dickinson and Co (BDX)” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/hbk-sorce-advisory-llc-buys-shares-of-3961-becton-dickinson-and-co-bdx/1940496.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.